↓ Skip to main content

Dove Medical Press

Article Metrics

Management of patients with resistant hypertension: current treatment options

Overview of attention for article published in Integrated Blood Pressure Control, October 2013
Altmetric Badge

Mentioned by

googleplus
1 Google+ user

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
81 Mendeley
Title
Management of patients with resistant hypertension: current treatment options
Published in
Integrated Blood Pressure Control, October 2013
DOI 10.2147/ibpc.s33984
Pubmed ID
Authors

Tanja Dudenbostel, Nilay Kumar, Calhoun

Abstract

Resistant hypertension (RHTN) is an increasingly common clinical problem that is often heterogeneous in etiology, risk factors, and comorbidities. It is defined as uncontrolled blood pressure on optimal doses of three antihypertensive agents, ideally one being a diuretic. The definition also includes controlled hypertension with use of four or more antihypertensive agents. Recent observational studies have advanced the characterization of patients with RHTN. Patients with RHTN have higher rates of cardiovascular events and mortality compared with patients with more easily controlled hypertension. Secondary causes of hypertension, including obstructive sleep apnea, primary aldosteronism, renovascular disease, are common in patients with RHTN and often coexist in the same patient. In addition, RHTN is often complicated by metabolic abnormalities. Patients with RHTN require a thorough evaluation to confirm the diagnosis and optimize treatment, which typically includes a combination of lifestyle adjustments, and pharmacologic and interventional treatment. Combination therapy including a diuretic, a long-acting calcium channel blocker, an angiotensin-converting enzyme inhibitor, a beta blocker, and a mineralocorticoid receptor antagonist where warranted is the classic regimen for patients with treatment-resistant hypertension. Mineralocorticoid receptor antagonists like spironolactone or eplerenone have been shown to be efficacious in patients with RHTN, heart failure, chronic kidney disease, and primary aldosteronism. Novel interventional therapies, including baroreflex activation and renal denervation, have shown that both of these methods may be used to lower blood pressure safely, thereby providing exciting and promising new options to treat RHTN.

Mendeley readers

The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 2 2%
Argentina 1 1%
Australia 1 1%
Unknown 77 95%

Demographic breakdown

Readers by professional status Count As %
Student > Master 17 21%
Student > Postgraduate 10 12%
Researcher 9 11%
Student > Bachelor 9 11%
Other 8 10%
Other 18 22%
Unknown 10 12%
Readers by discipline Count As %
Medicine and Dentistry 48 59%
Nursing and Health Professions 6 7%
Agricultural and Biological Sciences 5 6%
Pharmacology, Toxicology and Pharmaceutical Science 2 2%
Psychology 2 2%
Other 4 5%
Unknown 14 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 October 2013.
All research outputs
#2,015,866
of 3,629,728 outputs
Outputs from Integrated Blood Pressure Control
#7
of 16 outputs
Outputs of similar age
#49,799
of 95,592 outputs
Outputs of similar age from Integrated Blood Pressure Control
#1
of 3 outputs
Altmetric has tracked 3,629,728 research outputs across all sources so far. This one is in the 25th percentile – i.e., 25% of other outputs scored the same or lower than it.
So far Altmetric has tracked 16 research outputs from this source. They receive a mean Attention Score of 1.3. This one scored the same or higher as 9 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 95,592 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them